ALLMedicine™ Ankylosing Spondylitis Center
Research & Reviews 2,953 results
International Journal of Rheumatic Diseases; Gezer HH, Duruöz MT
Jan 27th, 2022 - This study aimed to assess patients with axial psoriatic arthritis (AxPsA) using the Canadian Spondyloarthritis Research Consortium (SPARCC) sacroiliac joint (SIJ) scores and to seek correlations between magnetic resonance imaging (MRI) scores and...
Journal of Clinical Rheumatology : Practical Reports on R... Duro T, Li S et. al.
Jan 26th, 2022 - Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.|2022|Duro T,Li S,Jose D,Khawar T,|
https://doi.org/10.1007/s00223-021-00933-1 10.1136/annrheumdis-2013-203425 10.1016/j.berh.2010.01.005 10.1002/art.41667
Calcified Tissue International; Lems W, Miceli-Richard C et. al.
Jan 24th, 2022 - Spondyloarthropathies (SpA) are common systemic inflammatory rheumatic diseases, in which, as in other rheumatic diseases, levels of markers of bone resorption are elevated, leading to bone loss and elevated risk of vertebral fractures. However, t...
https://doi.org/10.1186/s12865-022-00476-6 10.1016/j.gene.2017.09.049 10.3389/fimmu.2019.01232 10.1016/j.autrev.2020.102584 10.1016/j.intimp.2019.03.026 10.1007/s12016-019-08745-w 10.1186/s13075-019-1827-9 10.1159/000484250 10.1007/bf00832006 10.1186/s12967-019-1774-x 10.1002/art.40468 10.1016/j.berh.2014.10.008 10.1034/j.1600-6143.2002.020107.x 10.1002/art.1780270401 10.3389/fonc.2020.00154 10.18632/aging.102979 10.4238/2015.May.18.6 10.3390/ijms17122126 10.1371/journal.pgen.1001195 10.4081/reumatismo.2020.1235 10.1038/s12276-020-0445-6 10.1016/j.canlet.2019.12.038 10.3389/fimmu.2020.02031 10.3892/or.2020.7588 10.1002/iid3.485 10.1096/fj.202001078R 10.1111/mmi.14174 10.1128/JB.01323-07 10.1002/stem.781 10.1371/journal.pone.0046799 10.1371/journal.pone.0163277 10.1016/j.mcp.2019.101504 10.1016/j.bone.2017.05.009 10.4161/epi.19373
BMC Immunology; Liang T, Chen J et. al.
Jan 24th, 2022 - This study was aimed to identify the biomarkers for diagnosis and reveal the immune microenvironment changes in ankylosing spondylitis (AS). GSE73754 was downloaded for the co-expression network construction and immune cell analyses. Flow cytometr...
https://doi.org/10.1186/s13075-021-02695-5 10.1007/s11926-017-0681-5 10.1002/art.1780270401 10.1136/annrheumdis-2014-205178 10.1002/art.23471 10.1002/art.23901 10.1186/ar2794 10.1177/1759720X20906040 10.1136/annrheumdis-2017-211544 10.1136/annrheumdis-2016-210770 10.1136/annrheumdis-2019-215427 10.1016/j.reuma.2017.08.008 10.1136/ard.2004.020503 10.1186/ar4144 10.1186/s13075-019-1913-z 10.1136/annrheumdis-2011-201252 10.1136/annrheumdis-2018-213184 10.1136/ard.2003.018457 10.1111/1756-185X.13270 10.1093/rheumatology/kez363 10.1136/annrheumdis-2017-211734 10.1136/ard.2010.138594 10.1093/rheumatology/kes057 10.1016/j.reuma.2013.12.006 10.1136/ard.2008.094870 10.1136/annrheumdis-2017-211989 10.1136/ard.2004.022038
Arthritis Research & Therapy; Llop M, Moreno M et. al.
Jan 23rd, 2022 - To evaluate the influence of the disease activity on radiographic progression in axial spondyloarthritis (axSpA) patients treated with TNF inhibitors (TNFi). The study included 101 axSpA patients from the Spanish Register of Biological Therapy in ...
Guidelines 11 results
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.
Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologi...
Pain Physician; Kaye AD, Manchikanti L et. al.
Feb 6th, 2019 - Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive procedures to target therapeutics to the central nervous system and the spinal column. A subset of patients encountered in ...
Mar 6th, 2018 - Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the ...
Annals of the Rheumatic Diseases; van der Heijde D, Ramiro S et. al.
Jan 15th, 2017 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with...
Annals of the Rheumatic Diseases; Agca R, Heslinga SC et. al.
Oct 5th, 2016 - Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommend...
Drugs 772 results see all →
Clinicaltrials.gov 133 results
Jan 19th, 2022 - Yoga is an ancient discipline that emerged in India thousands of years ago, designed to bring balance and health to the physical, mental, emotional and spiritual dimensions of the individual.Due to its therapeutic effects, yoga can be considered a...
Jan 11th, 2022 - This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability ov...
Jan 5th, 2022 - The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) a...
Dec 20th, 2021 - Axial spondyloarthritis (axSpA), which encompasses radiographic axSpA (r-axSpA, also known as ankylosing spondylitis [AS]) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chroni...
Dec 14th, 2021 - The purpose of this study is to demonstrate the impact of secukinumab on progression of structural damage in the spine, as measured by the mSASSS in patients with AS.
News 564 results
Jan 26th, 2022 - It's official: full data from a randomized trial evaluating safety of the oral JAK inhibitor tofacitinib (Xeljanz), approved for treating rheumatoid arthritis and related disorders as well as ulcerative colitis, are now published -- and they are n...
Dec 16th, 2021 - The US Food and Drug Administration (FDA) approved a supplemental new drug application for tofacitinib (Xeljanz, Xeljanz XR) that adds active ankylosing spondylitis in adults to its list of indications, according to a December 14 announcement from...
Dec 15th, 2021 - The US Food and Drug Administration has approved a 15-mg extended release tablet of upadacitinib (Rinvoq) for adults with psoriatic arthritis who had an inadequate response or intolerance to one or more anti-tumor necrosis factor drugs, manufactur...
Dec 7th, 2021 - Peripheral manifestations contribute significantly to disease activity in adults with spondyloarthritis (SpA), point toward a generally worse prognosis, and play a big role in defining the phenotypic clustering of the heterogenous disease, accordi.
Dec 7th, 2021 - Peripheral manifestations contribute significantly to disease activity in adults with spondyloarthritis (SpA), point toward a generally worse prognosis, and play a big role in defining the phenotypic clustering of the heterogenous disease, accordi...